Biomarker Insights最新文献

筛选
英文 中文
The Genoa Vascular Biobank: A Today Resource for Future Perspectives in Vascular Research. 热那亚血管生物库:血管研究未来前景的今天资源。
IF 3.4
Biomarker Insights Pub Date : 2025-07-13 eCollection Date: 2025-01-01 DOI: 10.1177/11772719251324322
Chiara Barisione, Jorge Miguel Mena Vera, Caterina Ivaldo, Silvia Ortona, Pier Francesco Ferrari, Paola Visconti, Michele Paudice, Martina Bastianon, Caterina Melani, Gaddiel Mozzetta, Valerio Vellone, Giovanni Pratesi, Domenico Palombo
{"title":"The Genoa Vascular Biobank: A Today Resource for Future Perspectives in Vascular Research.","authors":"Chiara Barisione, Jorge Miguel Mena Vera, Caterina Ivaldo, Silvia Ortona, Pier Francesco Ferrari, Paola Visconti, Michele Paudice, Martina Bastianon, Caterina Melani, Gaddiel Mozzetta, Valerio Vellone, Giovanni Pratesi, Domenico Palombo","doi":"10.1177/11772719251324322","DOIUrl":"10.1177/11772719251324322","url":null,"abstract":"<p><strong>Background: </strong>Biological knowledge and patient care have been significantly improved by the emergence of big data analysis and -omics sciences, requiring high quality standards for biospecimen and data collection. Biobanks are complex and dynamic units designated to fulfill these needs.</p><p><strong>Objectives: </strong>The Genoa Vascular Biobank (GTB-VD) is a collaborative network between the IRCCS Ospedale Policlinico San Martino (Centre of Biological Resources), and the University of Genoa (Vascular and Endovascular Surgery Unit; Anatomic Pathology Unit; Laboratory of Clinical and Experimental Vascular Biology). This work describes workflow, ethic and governance requirements, demographic and clinical characteristics of subjects enrolled in the GTB-VD, and the volume of open or endovascular surgical interventions.</p><p><strong>Design: </strong>The GTB-VD recruits patients undergoing surgical repair for carotid artery stenosis (CS) and abdominal aortic aneurysm (AAA), enrolled on the basis of selection criteria and subdivided for pathology and type of intervention, upon informed consent.</p><p><strong>Methods: </strong>Biospecimens comprise serum, plasma, whole blood, peripheral blood mononuclear cells, and urine (from AAA only), stored at -80°C; lesions from open surgeries are frozen and formalin fixed paraffin embedded. Samples are associated with donor's clinical data through pseudonymization to prevent patient identification. Data accuracy and sample quality are ensured by harmonized standard operative procedures.</p><p><strong>Results: </strong>From 2018 to the end of 2023, 442 CS (distinguished into severe-asymptomatic or symptomatic, displaying a ratio of 5:1) and 214 AAA have been collected. CS is more frequently associated with diabetes and peripheral artery diseases, AAA with pulmonary history, and renal function impairment. Open surgery is more used for CS and endovascular for AAA.</p><p><strong>Conclusion: </strong>The GTB-VD, as organized, represents an \"<i>unicum</i>\" in our Country; it supports studies to identify molecular targets and biomarkers associated with specific arteriopathy, for developing secondary prevention strategies and minimally invasive, in situ therapies. Collaborative studies and sample sharing are welcome.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251324322"},"PeriodicalIF":3.4,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pro-Inflammatory Cytokines in Patients With Chronic Phase-Chronic Myeloid Leukaemia Treated With Imatinib: Any Role in the Monitoring of Treatment Response? 伊马替尼治疗慢性粒细胞白血病患者的促炎细胞因子:在监测治疗反应中有何作用?
IF 3.4
Biomarker Insights Pub Date : 2025-06-30 eCollection Date: 2025-01-01 DOI: 10.1177/11772719251351687
Kehinde A Taiwo, Ibrahim O Ahmed, Muritala A Asafa, Olusola J Olarewaju, Oludolapo A Omoyiola, Olatokunbo O Oguns, Temilola O Owojuyigbe, Rahman A Bolarinwa
{"title":"Pro-Inflammatory Cytokines in Patients With Chronic Phase-Chronic Myeloid Leukaemia Treated With Imatinib: Any Role in the Monitoring of Treatment Response?","authors":"Kehinde A Taiwo, Ibrahim O Ahmed, Muritala A Asafa, Olusola J Olarewaju, Oludolapo A Omoyiola, Olatokunbo O Oguns, Temilola O Owojuyigbe, Rahman A Bolarinwa","doi":"10.1177/11772719251351687","DOIUrl":"10.1177/11772719251351687","url":null,"abstract":"<p><strong>Background: </strong>Cancers cause changes in the levels of inflammatory cytokines by inhibiting or promoting their production thus affecting the immune system. The measurement of serum levels of cytokines may be useful in assessing these immunological changes and invariably assessing cancer status.</p><p><strong>Objectives: </strong>To investigate the effect of imatinib mesylate (glivec<sup>®</sup>) on the serum levels of interleukins (IL-6 and IL-10), and C-reactive protein (CRP) in patients with chronic phase chronic myeloid leukaemia (CP-CML).</p><p><strong>Design: </strong>This prospective cohort study included 26 imatinib naïve CP-CML patients with no other co-morbidities and 26 age and sex-matched healthy controls.</p><p><strong>Method: </strong>Serum levels of interleukins (IL6 and 10) and CRP were determined using the ELISA method at recruitment for both patients and controls and repeated for the CML patients at 3 months into imatinib therapy.</p><p><strong>Results: </strong>The mean serum levels of IL-6 and CRP were significantly higher in CP-CML than in the controls at recruitment 439.83 ± 167.52 versus 39.62 ± 10.11 pg/ml, (<i>t</i> = 8.720 <i>P</i> ⩽ .0001), (8.45 ± 2.88 vs 2.86 ± 1.08 mg/l; <i>t</i> = 6.729 <i>P</i> ⩽ .0001) respectively. In contrast, the mean of the IL-10 in the controls (36.63 ± 12.43) was noticed to be significantly higher than the patients (22.88 ± 4.76 vs 36.63 ± 12.43 pg/ml; <i>t</i> = -3.851 <i>P</i> = .003). Interestingly, there was a significant drop in the serum levels of IL-6 (439.83 ± 167.52 vs 46.85 ± 14.48 pg/ml, (<i>t</i> = 8.055 <i>P</i> ⩽ .0001) and CRP (8.45 ± 2.88 mg/l vs 4.24 ± 1.57; <i>t</i> = 4.305 <i>P</i> = .0001) in the CML subjects 3 months into imatinib therapy. Only IL-10 had a non-significant drop in the CML subjects after 3 months of imatinib therapy. Method validation of these biomarkers was done using the Receiver operating characteristic (ROC) curve which revealed an area under the curve (AUC) of 1.000 for both IL-6 and CRP and 0.152 for IL-10.</p><p><strong>Conclusion: </strong>The study has concluded that treatment naïve CML is associated with a significant elevation of pro-inflammatory cytokines (IL-6 and CRP) and treatment with imatinib led to a significant decline in the serum levels of these markers suggesting that IL-6 and CRP could be useful as adjunct in the monitoring of CML treatment.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251351687"},"PeriodicalIF":3.4,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Latest Advances in Structural Insights and Quantification Techniques for Type I Collagen Biomarkers: A path toward standardization? I型胶原生物标志物的结构洞察和定量技术的最新进展:走向标准化的道路?
IF 3.4
Biomarker Insights Pub Date : 2025-05-24 eCollection Date: 2025-01-01 DOI: 10.1177/11772719251336274
Justine Demeuse, Alix Mackowiak, Elodie Grifnée, Philippe Massonnet, Loreen Huyghebaert, Thomas Dubrowski, Stéphanie Peeters, Caroline Le Goff, Etienne Cavalier
{"title":"Latest Advances in Structural Insights and Quantification Techniques for Type I Collagen Biomarkers: A path toward standardization?","authors":"Justine Demeuse, Alix Mackowiak, Elodie Grifnée, Philippe Massonnet, Loreen Huyghebaert, Thomas Dubrowski, Stéphanie Peeters, Caroline Le Goff, Etienne Cavalier","doi":"10.1177/11772719251336274","DOIUrl":"10.1177/11772719251336274","url":null,"abstract":"<p><p>With an aging population, the demand for sensitive and specific biomarkers to assess bone turnover has surged. Bone turnover involves 2 key processes: bone formation, during which Type I procollagen is cleaved into Type I collagen and subsequently mineralized into bone, and bone resorption, during which Type I collagen is demineralized and degraded into peptides by cathepsin K. To identify biomarkers that accurately reflect these processes, extensive efforts have been made to characterize the peptides generated during both formation and resorption. Over the years, numerous biomarkers have been discovered for various disorders. However, despite their clinical utility, many of these markers lack specificity. This is due to factors such as the degradation of trimers into monomers, the coexistence of multiple peptide species arising from the unpredictable cleavage of Type I collagen/procollagen by cathepsin K and metalloproteinases, and the lack of assay standardization. Standardization is further hindered by the incomplete characterization of many of these peptides. For accurate assay development, a gold-standard technique like LC-MS/MS is essential, requiring full peptide characterization during method development. This review aims to present recent advances in the characterization of Type I collagen-derived peptides, providing a foundation for improved biomarker standardization and application in clinical practice.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251336274"},"PeriodicalIF":3.4,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pre-diagnostic Demographic, Lifestyle, and Health History Factors in Association with Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression in Colorectal Cancer Tissue. 结直肠癌组织中与分泌蛋白酸性和富含半胱氨酸(SPARC)表达相关的诊断前人口统计学、生活方式和健康史因素
IF 3.4
Biomarker Insights Pub Date : 2025-05-21 eCollection Date: 2025-01-01 DOI: 10.1177/11772719251339955
Umaimah Zanif, Jaclyn Parks, Isabella Tai, Stephen Yip, Sindy Babinszky, Katy Milne, Peter Watson, Rachel A Murphy, Parveen Bhatti
{"title":"Pre-diagnostic Demographic, Lifestyle, and Health History Factors in Association with Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression in Colorectal Cancer Tissue.","authors":"Umaimah Zanif, Jaclyn Parks, Isabella Tai, Stephen Yip, Sindy Babinszky, Katy Milne, Peter Watson, Rachel A Murphy, Parveen Bhatti","doi":"10.1177/11772719251339955","DOIUrl":"10.1177/11772719251339955","url":null,"abstract":"<p><strong>Background: </strong>Demographic, health history, and lifestyle factors have been associated with prognosis of colorectal cancer (CRC), but mechanisms underlying these associations remain poorly understood. A compelling mechanism involves changes in expression of tumor markers that influence treatment outcomes, such as secreted protein acidic and rich in cysteine (SPARC), lower levels of which have previously been associated with poorer CRC prognosis.</p><p><strong>Objective: </strong>We explored the association of factors that have been previously associated with CRC prognosis with expression of SPARC in tumor tissues.</p><p><strong>Design: </strong>We conducted a prospective evaluation of 50 participants of a longitudinal cohort study that went on to develop CRC.</p><p><strong>Methods: </strong>Tumor and normal tissue cores were taken from formalin-fixed paraffin-embedded (FFPE) blocks of incident CRC cases and were used to create tissue microarrays (TMAs). Slides created from the TMAs were stained with SPARC antibodies and analyzed to calculate H-scores for both epithelial and non-epithelial components of tumor and normal tissues. H-scores were ln-transformed and analyzed in association with demographic, lifestyle, and health history factors assessed before cancer diagnosis using linear regression models.</p><p><strong>Results: </strong>In CRC tumor epithelium, smoking was associated with a 0.53-fold lower level of SPARC expression (<i>P</i> = .054). Higher income was associated with a 1.33-fold greater level of SPARC expression in tumor non-epithelial tissue (<i>P</i> = .041). Higher cancer stage was associated with a 0.74-fold lower level of non-epithelial tumor SPARC expression (<i>P</i> = .040). In the epithelial component of normal colorectal tissues, higher fruit consumption was associated with a 2.74-fold greater SPARC H-score (<i>P</i> = .002).</p><p><strong>Conclusions: </strong>The associations we observed for smoking, income, and cancer stage with SPARC in tumor tissue are consistent with previously established associations of these factors with CRC prognosis. Larger studies with prognostic data are needed, but our results suggest that differences in SPARC expression may contribute to previously observed impacts of various factors on CRC prognosis.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251339955"},"PeriodicalIF":3.4,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144144139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Poor Abilities of Noninvasive Biomarkers to Assess Esophagogastric Varices and Portal Hypertensive Gastropathy. 无创生物标志物评估食管胃静脉曲张和门脉高压性胃病的能力较差。
IF 3.4
Biomarker Insights Pub Date : 2025-05-16 eCollection Date: 2025-01-01 DOI: 10.1177/11772719251339185
Kodjo Kunale Abassa, Xiaoning Guo, Shuyan Tan, Zhiling Liang, Siwei Tan
{"title":"Poor Abilities of Noninvasive Biomarkers to Assess Esophagogastric Varices and Portal Hypertensive Gastropathy.","authors":"Kodjo Kunale Abassa, Xiaoning Guo, Shuyan Tan, Zhiling Liang, Siwei Tan","doi":"10.1177/11772719251339185","DOIUrl":"10.1177/11772719251339185","url":null,"abstract":"<p><strong>Background: </strong>Noninvasive and cost-effective markers are needed to replace esophagogastroduodenoscopy in the screening for severe esophagogastric varices (EGVs) and portal hypertensive gastropathy (PHG).</p><p><strong>Objective: </strong>This study evaluated the performances of several commonly used fibrosis markers in assessing EGVs and PHG in cirrhosis patients.</p><p><strong>Design: </strong>Retrospective cohort study.</p><p><strong>Methods: </strong>A series of 323 patients with cirrhosis were consecutively enrolled and endoscopically followed up until variceal eradication was achieved. The Fibrosis-4 (FIB-4) score, albumin-bilirubin (ALBI) index, aspartate aminotransferase (AST)-to-alanine aminotransferase (ALT) ratio (AAR), AST-to-platelet ratio index (APRI), gamma-glutamyl transpeptidase-to-platelet ratio (GPR), and Lok score were calculated for each patient upon first admission. The performances of these markers in assessing EGVs and PHG were determined.</p><p><strong>Results: </strong>In the screening for clinically relevant esophageal varices (CREVs), none of the markers showed a significant ability to differentiate CREVs from non-CREVs (<i>P</i> > .05). The AAR (area under the curve (AUC): 0.581, sensitivity: 52.0%, specificity: 66.1%, <i>P</i> = .033) and the GPR (AUC = 0.596, sensitivity: 64.0%, specificity: 50.0%, <i>P</i> = .033) fairly differentiated clinically relevant gastric varices (CRGVs) from non-CRGVs patients. Moreover, no correlation was noted between PHG and CREVs (<i>r</i> = .016, <i>P</i> <i>=</i> .778) or between PHG and CRGVs (<i>r</i> = -.024, <i>P</i> = .666). Furthermore, no difference in the severity of PHG before and after variceal eradication was detected (<i>P</i> = .224).</p><p><strong>Conclusion: </strong>The studied markers revealed poor to no ability to assess EGVs or PHG. Hence, they cannot be used to substitute EGD in the screening for EGVs. Furthermore, endoscopic eradication of EGVs did not affect the severity of PHG.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251339185"},"PeriodicalIF":3.4,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144095423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Procalcitonin as a Prognostic Biomarker in Hospitalized COVID-19 Patients: A Comparative Analysis. 降钙素原作为COVID-19住院患者预后生物标志物的作用:比较分析
IF 3.4
Biomarker Insights Pub Date : 2025-05-15 eCollection Date: 2025-01-01 DOI: 10.1177/11772719241296624
Shahin Isha, Lekhya Raavi, Sadhana Jonna, Hrishikesh Nataraja, Emily C Craver, Anna Jenkins, Abby J Hanson, Prasanth Balasubramanian, Arvind Balavenkataraman, Aysun Tekin, Vikas Bansal, Swetha Reddy, Sean M Caples, Syed Anjum Khan, Nitesh K Jain, Abigail T LaNou, Rahul Kashyap, Rodrigo Cartin-Ceba, Ricardo Diaz Milian, Carla P Venegas, Anna B Shapiro, Anirban Bhattacharyya, Sanjay Chaudhary, Sean P Kiley, Quintin J Quinones, Neal M Patel, Pramod K Guru, Pablo Moreno Franco, Archana Roy, Devang K Sanghavi
{"title":"Role of Procalcitonin as a Prognostic Biomarker in Hospitalized COVID-19 Patients: A Comparative Analysis.","authors":"Shahin Isha, Lekhya Raavi, Sadhana Jonna, Hrishikesh Nataraja, Emily C Craver, Anna Jenkins, Abby J Hanson, Prasanth Balasubramanian, Arvind Balavenkataraman, Aysun Tekin, Vikas Bansal, Swetha Reddy, Sean M Caples, Syed Anjum Khan, Nitesh K Jain, Abigail T LaNou, Rahul Kashyap, Rodrigo Cartin-Ceba, Ricardo Diaz Milian, Carla P Venegas, Anna B Shapiro, Anirban Bhattacharyya, Sanjay Chaudhary, Sean P Kiley, Quintin J Quinones, Neal M Patel, Pramod K Guru, Pablo Moreno Franco, Archana Roy, Devang K Sanghavi","doi":"10.1177/11772719241296624","DOIUrl":"10.1177/11772719241296624","url":null,"abstract":"<p><strong>Background: </strong>Procalcitonin (PCT) is recognized as an inflammatory biomarker, often elevated in COVID-19 pneumonia alongside other biomarkers. Understanding its association with severe outcomes and comparing its predictive ability with other biomarkers is crucial for clinical management.</p><p><strong>Objectives: </strong>This retrospective multicenter observational study aimed to investigate the association between PCT levels and adverse outcomes in hospitalized COVID-19 patients. Additionally, it sought to compare the predictive performance of various biomarkers.</p><p><strong>Design: </strong>The study analyzed data from the Society of Critical Care Medicine (SCCM) Viral Infection and Respiratory Illness Universal Study (VIRUS) registry, comprising COVID-19 patients hospitalized across multiple Mayo Clinic sites between March 2020 and June 2022.</p><p><strong>Methods: </strong>A total of 7851 adult COVID-19 patients were included. Patients were categorized into 6 groups based on the worst WHO ordinal scale. Multivariate models were constructed using peak biomarker levels within 72 hours of admission, adjusted for confounders.</p><p><strong>Results: </strong>Elevated PCT levels were independently associated with increased odds of adverse outcomes, including ICU admission (adjusted odds ratio [aOR] 1.32, 95%CI 1.27-1.38), IMV requirement (aOR 1.35, 95%CI: 1.28-1.42), and in-hospital mortality (aOR 1.30, 95%CI: 1.22-1.37). A 3.48-fold increase in IMV requirement and 3.55 times increase in in-hospital mortality were noted with peak PCT ⩾ 0.25 ng/ml. Similar associations were observed with other biomarkers like NLR (AUC 0.730), CRP, IL-6, LDH (AUC 0.800), and D-dimer (AUC 0.719). Models incorporating NLR, LDH, D-dimer, and PCT demonstrated the highest predictive accuracy, with a combined model exhibiting an area under the curve (AUC) of 0.826 (95%CI 0.803-0.849).</p><p><strong>Conclusions: </strong>Higher PCT levels were significantly linked to worse outcomes in COVID-19 patients, emphasizing its potential as a prognostic marker. Biomarker-based predictive models, particularly those including PCT, showed promising utility for risk assessment and clinical decision-making. Further prospective studies are warranted to validate these findings on a larger scale.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719241296624"},"PeriodicalIF":3.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144095458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[18F]PSMA-1007 PET/MR as a Precision Biomarker for Early Detection of Biochemical Recurrence in Prostate Cancer at Very Low PSA Levels. [18]PSMA-1007 PET/MR在极低PSA水平前列腺癌生化复发早期检测中的应用。
IF 3.4
Biomarker Insights Pub Date : 2025-03-12 eCollection Date: 2025-01-01 DOI: 10.1177/11772719251324307
Ko-Han Lin, Tzu-Chun Wei, Shu-Huei Shen, William Ji-Shien Huang, Mei-Hua Chuang, Nan-Jing Peng, Wen-Tao Huang, Yuh-Feng Wang
{"title":"[<sup>18</sup>F]PSMA-1007 PET/MR as a Precision Biomarker for Early Detection of Biochemical Recurrence in Prostate Cancer at Very Low PSA Levels.","authors":"Ko-Han Lin, Tzu-Chun Wei, Shu-Huei Shen, William Ji-Shien Huang, Mei-Hua Chuang, Nan-Jing Peng, Wen-Tao Huang, Yuh-Feng Wang","doi":"10.1177/11772719251324307","DOIUrl":"10.1177/11772719251324307","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) patients with biochemical recurrence (BCR) following radical prostatectomy or radiation therapy often present with very low prostate-specific antigen (PSA) levels (⩽0.5 ng/mL). Accurate detection of recurrence at such low levels is crucial for guiding treatment decisions.</p><p><strong>Objectives: </strong>To assess the diagnostic efficacy of [<sup>18</sup>F]PSMA-1007 PET/MR (PSMA-PETMR) in detecting BCR of PCa in patients with very low PSA levels.</p><p><strong>Design: </strong>A prospective study conducted between May 2021 and January 2023, with data subsequently analyzed retrospectively after a 2-year follow-up.</p><p><strong>Methods: </strong>The cohort comprised 157 PCa patients with BCR, of whom 52 had PSA levels ⩽ 0.5 ng/mL and underwent PSMA-PETMR imaging. The imaging protocol incorporated multiparametric MRI (mpMRI) and PET acquisitions, with lesion classification following PSMA-RADS version 1.0. Detection rates of recurrent lesions, including local recurrence, lymph node metastasis, and skeletal metastasis, were evaluated.</p><p><strong>Results: </strong>PSMA-PETMR exhibited a 63.5% detection rate for recurrent PCa at low PSA levels, surpassing traditional diagnostic methods. Thirty-four local recurrences, 12 metastatic lymph nodes, and 4 skeletal metastases were identified. Follow-up imaging enhanced the detection rate to 73.1% by reclassifying initially equivocal findings. PSMA-PETMR influenced clinical decision-making in 17% of patients by facilitating personalized treatment strategies.</p><p><strong>Conclusion: </strong>PSMA-PETMR significantly improves the detection of recurrent PCa in patients with very low PSA levels, offering precise lesion localization and supporting personalized treatment approaches. Further studies are needed to optimize its clinical use and validate its long-term benefits.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251324307"},"PeriodicalIF":3.4,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11905080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endothelin-1 as a Candidate Biomarker of Systemic Sclerosis: A GRADE-Assessed Systematic Review and Meta-Analysis With Meta-Regression. 内皮素-1作为系统性硬化症的候选生物标志物:一项分级评估的系统评价和meta -回归分析
IF 3.4
Biomarker Insights Pub Date : 2025-02-21 eCollection Date: 2025-01-01 DOI: 10.1177/11772719251318555
Arduino A Mangoni, Angelo Zinellu
{"title":"Endothelin-1 as a Candidate Biomarker of Systemic Sclerosis: A GRADE-Assessed Systematic Review and Meta-Analysis With Meta-Regression.","authors":"Arduino A Mangoni, Angelo Zinellu","doi":"10.1177/11772719251318555","DOIUrl":"10.1177/11772719251318555","url":null,"abstract":"<p><strong>Background: </strong>There is an ongoing search for novel biomarkers of vascular dysfunction, extent of fibrosis and organ involvement in systemic sclerosis (SSc).</p><p><strong>Objectives: </strong>We critically appraised the studies investigating the circulating concentrations of endothelin-1 in SSc patients and healthy controls.</p><p><strong>Design: </strong>This was a systematic review with meta-analysis.</p><p><strong>Data sources and methods: </strong>We searched electronic databases (PubMed, Scopus, and Web of Science) from inception to 15 June 2024. We assessed the risk of bias and the certainty of evidence using the JBI Critical Appraisal Checklist and GRADE, respectively.</p><p><strong>Results: </strong>Endothelin-1 concentrations were significantly higher in SSc patients than in controls (26 studies; standardised mean difference, SMD = 0.98, 95% CI 0.73-1.23, <i>P</i> < .001; moderate certainty of evidence). In SSc patients, there were no significant differences in endothelin-1 concentrations between those with limited and diffuse cutaneous SSc (10 studies; SMD = 0.32, 95% CI -0.07 to 0.71 <i>P</i> = .11; very low certainty), and with and without digital ulcers (5 studies; SMD = 0.82, 95% CI -0.06 to 1.69, <i>P</i> = .066; very low certainty), pulmonary arterial hypertension (7 studies; SMD = 0.22, 95% CI -0.01 to 0.45, <i>P</i> = .066; very low certainty) or interstitial lung disease (3 studies; SMD = 0.09, 95% CI -0.18 to 0.35, <i>P</i> = .51; very low certainty). There was limited evidence in SSc patients with different video capillaroscopy pattern and telangiectasias. Subgroup and meta-regression analyses showed significant associations between the effect size and geographical location (studies investigating SSc patients and controls), year of publication (studies investigating SSc patients with limited and diffuse cutaneous SSc), and biological matrix assessed (studies investigating SSc patients with and without digital ulcers).</p><p><strong>Conclusion: </strong>The results of this systematic review and meta-analysis highlight the potential role of endothelin-1 as a candidate biomarker of SSc. Further research is warranted to determine the utility of measuring endothelin-1 in SSc subgroups with different extent of fibrosis and organ involvement.</p><p><strong>Registration: </strong>PROSPERO registration number - CRD42024566461.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251318555"},"PeriodicalIF":3.4,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143484403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Cohort Study on Dual Predictive Markers of Immune Combination Therapy for Advanced Non-Small Cell Lung Cancer. 晚期非小细胞肺癌免疫联合治疗双预测标志物的队列研究
IF 3.4
Biomarker Insights Pub Date : 2025-02-14 eCollection Date: 2025-01-01 DOI: 10.1177/11772719251319641
Maike Zheng, Mingming Hu, Yanxia Liu, Xiaomi Li, Guirong Wang, Tongmei Zhang, Yan Zhao
{"title":"A Cohort Study on Dual Predictive Markers of Immune Combination Therapy for Advanced Non-Small Cell Lung Cancer.","authors":"Maike Zheng, Mingming Hu, Yanxia Liu, Xiaomi Li, Guirong Wang, Tongmei Zhang, Yan Zhao","doi":"10.1177/11772719251319641","DOIUrl":"10.1177/11772719251319641","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors (ICIs) hold a great promise in treatment of non-small cell lung cancer (NSCLC), while only a portion of patients benefited from the treatment, and others could not achieve optimal therapeutic effects from initial immunotherapy, even for those patients with PD-L1 (Programed cell death ligand 1) tested positive. However, the clinical markers for the selection of patients who will benefit from ICIs combination treatment beforehand are largely unknown.</p><p><strong>Objectives: </strong>The purpose of this study was to explore the non-invasive biomarkers that can predict the efficacy of immune combination therapy in advanced/metastatic NSCLC patients.</p><p><strong>Design: </strong>This study employed a retrospective cohort design to analyze dual predictive biomarkers in advanced non-small cell lung cancer (NSCLC) patients with immune combination therapy.</p><p><strong>Method: </strong>An analysis was conducted on baseline information of 144 patients with advanced/metastatic NSCLC who received ICIs treatment from the November of 2018 to the January of 2023 in Beijing Chest Hospital. We established a scoring group chart to make quantitative prediction for overall survival (OS) and progression-free survival (PFS) based on 4 variables, and set up the nomogram model as well as Decision curve analysis (DCA) to assess clinical benefits of ICIs combination in treatment of patients with advanced/metastatic NSCLC.</p><p><strong>Results: </strong>We found that serum globulin (GLB) >26.6 (g/L) (HR = 1.865, <i>P</i> = .002), absolute neutrophil counts (ANC) (10<sup>9</sup>/L) > 5 (HR = 2.146, <i>P</i> < .001), and bone metastasis (HR = 2.148, <i>P</i> < .001) were independent factors affecting the PFS of NSCLC patients. GLB > 26.6 (g/L) (HR = 1.741, <i>P</i> = .018), ANC (10<sup>9</sup>/L) >5 (HR = 1.807, <i>P</i> = .008), bone metastasis (HR = 1.651, <i>P</i> = .002), and PD-L1 Negative (HR = 2.432, <i>P</i> = .032) were independent factors affecting the OS of NSCLC patients. Same variables and cut-off value have good predictive efficacy in both PFS and OS.</p><p><strong>Conclusion: </strong>In patients with advanced/metastatic NSCLC receiving ICIs combination treatment, the GLB, ANC, bone metastasis, and PD-L1 may serve as useful predictive markers for the prognosis of NSCLC patients with ICIs combination treatment.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251319641"},"PeriodicalIF":3.4,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Prognostic Significance of TRs in Hepatocellular Carcinoma: Insights from TCGA and GEO Databases. 肝细胞癌中TRs的预后意义:来自TCGA和GEO数据库的见解。
IF 3.4
Biomarker Insights Pub Date : 2025-01-25 eCollection Date: 2025-01-01 DOI: 10.1177/11772719251315321
Hao Zhou, Weijie Wang, Ruopeng Liang, Rongtao Zhu, Jiahui Cao, Chenguang Sun, Yuling Sun
{"title":"The Prognostic Significance of TRs in Hepatocellular Carcinoma: Insights from TCGA and GEO Databases.","authors":"Hao Zhou, Weijie Wang, Ruopeng Liang, Rongtao Zhu, Jiahui Cao, Chenguang Sun, Yuling Sun","doi":"10.1177/11772719251315321","DOIUrl":"10.1177/11772719251315321","url":null,"abstract":"<p><strong>Background: </strong>Reduced expression of thyroid hormone receptors (TRs) has been observed in various human malignancies, though its predictive value in hepatocellular carcinoma (HCC) remains uncertain.</p><p><strong>Objective: </strong>To explore the predictive value of TRs in patients with hepatocellular carcinoma.</p><p><strong>Design: </strong>The design was bioinformatic analysis combined with experimental study.</p><p><strong>Methods: </strong>This study utilized Kaplan-Meier analysis of TR expression profiles from The Cancer Genome Atlas (TCGA). Expression levels of TRs in HCC and immune single cells were assessed using datasets from the Gene Expression Omnibus (GEO) and TCGA, analyzed with R software. Cox and logistic regression analyses were also conducted. Functional assays, including wound healing, CCK-8, and Transwell migration assays, were employed to investigate the role of the THRB gene.</p><p><strong>Results: </strong>Kaplan-Meier analysis revealed that low THRB expression was significantly associated with reduced overall survival (OS), 5-year OS and disease-specific survival (DSS) in HCC patients (<i>P</i> < 0.05), while no significant association was found with THRA expression. Both Cox regression and logistic regression identified low THRB expression as an independent risk factor for HCC. THRB expression was significantly downregulated in tumor tissues compared to non-tumorous tissues in 3 GEO datasets and the TCGA profile. Functional assays confirmed that THRB inhibited HCC cell proliferation and migration. Additionally, single-cell RNA sequencing revealed that THRB was primarily expressed in CD16+ monocytes within tumor tissues and was associated with a poor OS rate.</p><p><strong>Conclusion: </strong>Reduced THRB expression, but not THRA, was correlated with decreased OS in HCC patients.</p>","PeriodicalId":47060,"journal":{"name":"Biomarker Insights","volume":"20 ","pages":"11772719251315321"},"PeriodicalIF":3.4,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11765354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信